Coty shares dipped 20.2% to trade at $3.8750 on Thursday. These analysts made changes to their price targets on Coty following earnings announcement. Considering buying COTY stock? Here's what analysts think: Coty Inc. COTY posted mixed fourth-quarter fiscal results after the closing bell on Wednesday. The global beauty company reported fourth quarter revenue of $1.25 billion, surpassing Wall Street estimates of $1.20 billion. Coty posted an adjusted loss of 5 cents per share for the quarter, missing analys ...

Core Viewpoint - Yatsen Holding Limited reported strong financial results for the second quarter of 2025, highlighting significant growth in net revenues and improvements in operational efficiency, driven by successful product launches and strategic execution in the beauty industry [2][3][11]. Financial Performance - Total net revenues for Q2 2025 increased by 36.8% to RMB1.09 billion (US$151.7 million) from RMB794.5 million in the prior year [3][9]. - Net revenues from Skincare Brands surged by 78.7% year-over-year to RMB581.3 million (US$81.1 million), accounting for 53.5% of total net revenues [3][9]. - Gross profit rose by 39.5% to RMB850.4 million (US$118.7 million), with gross margin improving to 78.3% from 76.7% [3][9]. Operating Expenses - Total operating expenses increased by 21.7% to RMB905.9 million (US$126.5 million), but as a percentage of total net revenues, they decreased to 83.4% from 93.7% in the prior year [4][10]. - Fulfillment expenses were RMB63.3 million (US$8.8 million), down as a percentage of total net revenues to 5.8% from 6.4% [10]. - Selling and marketing expenses increased to RMB722.4 million (US$100.8 million), but decreased as a percentage of total net revenues to 66.5% from 68.6% [10]. Profitability Metrics - Loss from operations narrowed to RMB55.5 million (US$7.7 million) from RMB135.2 million in the prior year, with an operating loss margin improving to 5.1% from 17.0% [5][6]. - Net loss for Q2 2025 was RMB19.5 million (US$2.7 million), a significant reduction from RMB85.5 million in the prior year, resulting in a net loss margin of 1.8% compared to 10.8% [6][9]. - Non-GAAP net income for Q2 2025 was RMB11.5 million (US$1.6 million), a turnaround from a non-GAAP net loss of RMB74.9 million in the prior year [7][9]. Cash Flow and Balance Sheet - As of June 30, 2025, the company had cash, restricted cash, and short-term investments totaling RMB1.35 billion (US$188.6 million) [8]. - Net cash generated from operating activities for Q2 2025 was RMB77.7 million (US$10.8 million), compared to net cash used in operating activities of RMB148.2 million in the prior year [8]. Business Outlook - For Q3 2025, Yatsen expects total net revenues to be between RMB778.6 million and RMB880.1 million, representing a year-over-year increase of approximately 15% to 30% [11].

Brand Expansion & Marketing - K-Beauty brand Tirtir is launching a world tour to engage with fans, inspired by K-Pop's fan engagement strategies [1] - The brand aims to leverage its viral popularity to strengthen its global presence [1]

Market Overview - The market is experiencing structural differentiation, with AI and innovative pharmaceutical sectors showing volatility, while agriculture, beauty care, and retail sectors are leading in gains [1] - Defensive assets characterized by high dividends and stable cash flows continue to rise steadily [1] ETF Performance - The Hong Kong Dividend ETF (博时 513690) increased by 0.64%, with a turnover rate of 2.22% and a trading volume of 106 million [1] - The Low Volatility Dividend 100 ETF (红利低波100ETF 159307) rose by 0.55%, with a turnover rate of 0.57% and a trading volume of 7.022 million, showing a net inflow of 24 million over the past five days [3] - The All-Index Cash Flow ETF (全指现金流ETF基金 563830) increased by 0.36%, with a turnover rate of 17.20% and a trading volume of 3.987 million [3] Investment Insights - Recent market volatility has led to profit-taking in some popular sectors, indicating a potential internal market switch towards dividend and cash flow sectors that have seen sufficient pullbacks and increased attractiveness [5] - The logic favoring dividend sectors is reinforced by a low-interest-rate environment, which enhances the relative value of dividend stocks compared to other asset classes [3] - Historical data shows that when the dividend yield premium (股息率-10年国债收益率) is high, the CSI Dividend Total Return Index significantly outperforms the CSI All Share Total Return Index, particularly since 2021 [3] Sector Analysis - The Low Volatility Dividend 100 ETF currently has a dividend yield of 4.31%, with the top five sectors being banking (20.6%), transportation (13.3%), coal (7.4%), pharmaceuticals (6.2%), and basic chemicals (5.6%) [5] - The Hong Kong Dividend ETF has a dividend yield of 5.71%, with the leading sectors being real estate (17.6%), banking (15.3%), coal (10.8%), transportation (8.7%), and oil & petrochemicals (6.9%) [5] - The All-Index Cash Flow ETF has a dividend yield of 4.14%, with the top sectors being non-ferrous metals (15.2%), transportation (13.6%), food & beverage (10.8%), and oil & petrochemicals (9.5%) [5] Strategic Recommendations - Investors are encouraged to consider differentiated allocations between traditional dividend products and free cash flow products to enhance portfolio stability and return potential [4]

Summary of Key Points from the Conference Call Industry Overview - The report focuses on the **Chinese manufacturing and consumer sectors**, highlighting trends in **capital goods**, **technology**, **leisure**, and **beauty** industries [2][3][5]. Core Insights and Arguments 1. **Global Diversification Strategy**: Amid deflation and tariff uncertainties, mid-stream corporates are diversifying capacity globally as a key strategy [3][5]. 2. **Consumer Trends**: Leisure and beauty firms are experiencing solid growth through product differentiation aimed at self-rewarding consumers [3][5]. 3. **Sector Performance**: In July, **capital goods**, **software**, and **real estate** sectors gained the most wallet share, while **technology hardware** saw a significant decline in investor interest [5][10][16]. 4. **Investor Interest Shifts**: The top sectors for investor meetings in July were **technology**, **consumer**, and **financials**, contrasting with previous quarters [3][5]. 5. **Company Visits**: Notable companies visited include **BYD**, **Transsion**, **OmniVision**, and **Mindray**, indicating strong investor interest in these firms [3][5]. Additional Important Insights 1. **Sales Growth in SMID/Materials**: Companies like **Sunresin** and **Shengquan** reported robust sales growth, particularly in overseas markets, with significant projects in the pipeline [8][26][27]. 2. **Leisure and Beauty Sector Dynamics**: Companies such as **Yiwu CCC** and **Chicmax** are focusing on online sales channels and product launches to drive growth [32][37]. 3. **Transport Sector Recovery**: Express shipping prices are recovering, particularly in key regions like Guangdong, indicating a positive trend in logistics [8][32]. 4. **Technology Sector Challenges**: The **China Wafer Level CSP Company** is expanding overseas but faces flat demand in domestic smartphone markets [25]. 5. **Automotive Insights**: Visits to car dealers revealed a shift in consumer sentiment, with a positive outlook for brands like **BYD** amid changing market dynamics [40]. Conclusion The conference call provided a comprehensive overview of the current state of various sectors in China, emphasizing the importance of diversification, consumer trends, and shifts in investor interest. The insights gathered from company visits and sector performance highlight potential investment opportunities and risks in the evolving market landscape.

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was approximately $2.9 million, a 100% increase year over year and a slight sequential increase [5][17] - Gross margins improved to 43.6%, more than double the 20.3% reported in Q2 2024, and increased from 42.4% sequentially [5][18] - Adjusted EBITDA loss narrowed to negative $420,000 compared to negative $790,000 for the same period last year [6][20] - Net loss attributable to stockholders was $670,000, down from $890,000 in Q2 2024 [20] Business Line Data and Key Metrics Changes - Contract manufacturing revenue increased to $863,000, a 103% year over year increase from approximately $425,000 in 2024 [6] - Consumer products revenue increased by 95% year over year, driven by growth across the brand portfolio [12] Market Data and Key Metrics Changes - The company is seeing increased demand from domestic companies due to tariffs, although the impact on margins has been mild [35][36] - The partnership with Cintas remains strong, with ongoing sales of the SilverSeal product included in their wound care kits [7][75] Company Strategy and Development Direction - The company aims to continue expanding its contract manufacturing and white label business as a major driver of growth [11] - New product launches are planned, including an expanded beauty line and additional skincare solutions, reflecting the commitment to innovative, high-quality products [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive EBITDA by the end of the year and maintaining guidance for $13 million in revenue [15][81] - The company is preparing for potential economic downturns by focusing on high-margin consumer products and evaluating cost structures [66] Other Important Information - The company received $1 million in non-dilutive funding from STATA to support upcoming product launches and marketing initiatives [15][21] - The company has sufficient cash on hand, including recent capital raises, to support growth initiatives [21] Q&A Session Summary Question: Market opportunities for upcoming launches - Management discussed the potential for new digestive enzyme products, which target larger markets compared to existing products [22][23] Question: Retail strategy and brand consolidation - Management clarified that brands will maintain their unique identities and are currently exploring private label opportunities [25][27] Question: Manufacturing capacity and onboarding new customers - Current manufacturing capacity is underutilized, allowing for onboarding of new customers without immediate expansion [29][30] Question: Impact of tariffs on the business - Management noted a mild negative impact on margins but increased interest from domestic companies [35][36] Question: Status of AbbVie partnership - Management confirmed delays in the AbbVie project but remains optimistic about future developments [40][44] Question: New product details from Silly George - Management highlighted successful new product launches and strong sales performance [48][51] Question: Cash position and recession preparedness - Management is considering strategies for potential economic downturns while maintaining a focus on high-margin products [66] Question: Ranking of partnerships - Management identified key partnerships, including Cintas and AbbVie, as significant opportunities for growth [75]

Q2 2025 Financial Performance - Net sales increased by 2.3% to $106.3 million compared to Q2 2024[27] - Gross profit margin was 71.2% compared to 69.7% in Q2 2024[30] - Adjusted gross profit margin was 73.2% compared to 71.9% in Q2 2024[30] - SG&A expenses were $65.9 million compared to $45.4 million in Q2 2024[30] - Adjusted SG&A expenses were $54.3 million compared to $42.6 million in Q2 2024[30] - Net loss was $(7.7) million compared to a net income of $5.8 million in Q2 2024[34] - Adjusted EBITDA was $24.6 million compared to $32.1 million in Q2 2024[34] - Adjusted EBITDA margin was 23.1% compared to 30.8% in Q2 2024[34] Fiscal Year 2025 Guidance - Net sales are projected to be $410 million to $431 million, representing a -3% to +2% change compared to fiscal year 2024[40] - Adjusted gross profit margin is expected to be 70.5% to 71.5%[40] - Adjusted EBITDA margin is projected to be 20% to 22%[40]

Core Insights - ODDITY Tech Ltd. reported strong Q2 2025 results, with net sales and earnings exceeding estimates and showing year-over-year growth [1][3] - The company raised its full-year outlook, driven by robust top-line growth and strategic investments in innovation [2] Financial Performance - Adjusted EPS for Q2 was 92 cents, beating the estimate of 88 cents, and increased by 12.2% year-over-year [3] - Net sales reached $241.1 million, surpassing the estimate of $239 million, and grew by 25.1% from $192.8 million in the prior year [3] - Online DTC sales rose by 29.6% to $235.2 million, constituting 98% of total sales, up from 94% in the previous year [4] Margin and Cost Analysis - Gross profit was $174.4 million, a 25.3% increase from $139.1 million last year, with a gross margin of 72.3% [5] - SG&A expenses increased by 36.3% to $117.3 million, representing 48.6% of net sales, up 200 basis points year-over-year [5] - Operating income was $57.1 million, a 7.6% increase, while the operating margin declined to 23.7% [6] Strategic Developments - ODDITY's core brands, IL MAKIAGE and SpoiledChild, achieved double-digit online sales growth, supported by AI-driven personalization [10] - The company is on track to launch Brand 3 in Q4 2025, targeting the medical-grade dermatology segment, and Brand 4 is expected to launch in 2026 [11] - ODDITY raised $600 million through its first exchangeable note offering, indicating strong investor confidence [12] Future Guidance - For FY25, ODDITY expects net sales between $799 million and $804 million, reflecting 23-24% year-over-year growth [13] - Adjusted EBITDA is projected between $160 million and $162 million, with adjusted EPS expected between $2.06 and $2.09 [14] - For Q3 2025, net sales are anticipated to be between $144 million and $146 million, indicating year-over-year growth of 21-23% [14] Financial Health - As of June 30, 2025, ODDITY had cash and cash equivalents of $656.8 million, no long-term debt, and shareholders' equity of $351.2 million [9]

Financial Data and Key Metrics Changes - In Q2 2025, the company achieved a revenue growth of 26% to $509 million, generated adjusted EBITDA of $122 million, and free cash flow of $99 million, surpassing the entire free cash flow delivered in 2023 [4][30] - The adjusted diluted earnings per share for Q2 was $0.92, exceeding the guidance of $0.85 to $0.89 [29] - Gross margin expanded to 72.3%, exceeding guidance of 70.5% [28] Business Line Data and Key Metrics Changes - The company reported double-digit online growth in both its brands, Il Makiage and Spoiled Child, with Il Makiage expected to reach $1 billion in revenue by 2028 [12][24] - Spoiled Child is projected to cross $200 million in revenue this year, having launched only three years ago [13][42] Market Data and Key Metrics Changes - International sales represented approximately 15% of total net revenue, with a growth of over 40% in the first half of 2025, amounting to around $85 million [25][62] - The company is focusing on expanding its international presence, particularly in markets like the UK, Germany, Canada, Australia, and Israel, where it aims to replicate its U.S. success [27][62] Company Strategy and Development Direction - The company aims to become one of the largest beauty companies globally, with a focus on expanding its product offerings into healthcare, starting with dermatology [5][15] - Investments are being made in technology and new brands, with a strong emphasis on innovation and consumer demand for high-efficacy products [8][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another record-breaking year in 2025, with expected net revenue between $799 million and $804 million, representing a year-over-year growth of 23% to 24% [32] - The company plans to front-load investments in 2026, which may impact EBITDA margins in the first half of the year but is expected to maintain a long-term growth algorithm of 20% revenue growth and 20% adjusted EBITDA margin [34] Other Important Information - The company successfully issued its first convertible exchangeable note, upsized to $600 million, which significantly increased its cash position to $815 million [31] - The company is preparing for the launch of Brand Three, which will enter the medical-grade space, focusing on dermatology and offering both OTC and prescription products [13][15] Q&A Session Summary Question: What is driving the sequential compression in gross margin for Q3? - Management explained that gross margin is not a primary metric managed by teams, who focus on contribution margin, and that seasonality and lower revenue dollars in Q3 and Q4 contribute to the compression [39][40] Question: Will the company constrain growth on existing brands to manage future growth? - Management confirmed that they often constrain growth to ensure sustainable long-term growth, maintaining a commitment to 20% revenue growth and 20% adjusted EBITDA margin [51][52] Question: What are the investment plans for Brand Three and expected returns? - Management indicated that significant investments are being made in new brands and technology, with expectations of substantial future returns similar to past successful launches [56][57] Question: What are the growth drivers for international markets? - Management highlighted that international markets could be as large as the U.S. business, with strong growth in established markets and potential in new testing markets [62] Question: How will the go-to-market strategy differ for Brand Three? - Management stated that while the strategy will leverage existing technology and user base, it will also incorporate personalized treatments developed over two years [71][72] Question: What long-term revenue streams are anticipated from Brand Three? - Management outlined that Brand Three will operate as a telehealth platform with medical-grade products, focusing on compliance and leveraging existing user data for product development [78][80]

Financial Data and Key Metrics Changes - In Q2 2025, the company achieved a revenue growth of 26% to $509 million, generated adjusted EBITDA of $122 million, and free cash flow of $99 million, surpassing the entire free cash flow delivered in 2023 [5][25][32] - The adjusted EBITDA margin for Q2 was 28.8%, which compressed by approximately 350 basis points due to planned growth investments [31] - The gross margin expanded by 10 basis points year over year to 72.3%, exceeding guidance of 70.5% [30] Business Line Data and Key Metrics Changes - The company reported double-digit online growth in both its brands, Il Makiage and Spoiled Child, contributing to the overall revenue increase [26][10] - Il Makiage is on track to reach $1 billion in revenue by 2028, with international sales representing 15% of the business in 2024 [13][29] - Spoiled Child is projected to cross $200 million in revenue this year, having launched only three years ago [14] Market Data and Key Metrics Changes - International sales grew over 40% in the first half of 2025, amounting to approximately $85 million, with $75 million from established markets and $10 million from new testing markets [66] - The company is focusing on expanding its presence in international markets, which currently represent a smaller portion of its overall revenue compared to competitors [29][66] Company Strategy and Development Direction - The company aims to become one of the largest beauty companies globally, with a focus on expanding its online presence and entering the healthcare market [6][7] - Upcoming launches include Brand three, which will focus on medical-grade dermatology products, and Brand four next year [14][35] - Investments in technology and new brands are prioritized to sustain long-term growth and innovation [12][58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 20% revenue growth and 20% adjusted EBITDA margin in the long term, even without contributions from new brands [34][44] - The company is preparing for a strong finish to 2025, driven by a backlog of repeat sales and a focus on long-term initiatives [11][34] Other Important Information - The company generated $99 million in free cash flow in the first half of 2025, converting over 80% of adjusted EBITDA into free cash [32] - The company has a remaining buyback authorization of $103 million with no share repurchases year to date [33] Q&A Session Summary Question: What is driving the sequential compression in gross margin for Q3? - Management explained that gross margin is not a primary metric they manage to, and seasonal factors contribute to lower margins in the second half of the year due to repeat business dynamics [40][42] Question: Will Brand three's success impact growth management for existing brands? - Management confirmed that they do not need Brand three for their 2025 or 2026 outlook, as existing brands have sufficient growth potential [44][45] Question: What is the strategy for Brand three's launch? - Management indicated that a soft launch will occur in Q3 to test the market, with a full launch planned for Q4 [52] Question: What are the growth drivers for international markets? - Management highlighted that international markets are expected to grow significantly, with a focus on deeper penetration and new market entries [63][66] Question: How does Brand three differ from previous launches? - Management noted that Brand three will leverage advanced technology and personalized treatment plans, setting it apart from traditional offerings [72][74]